Journal Of The National Cancer Institute July 29
 

The Same Dose of Anthracycline Is Not Safe for Everyone Not all patients can tolerate the currently recommended cumulative dose of epirubicin. New models can help physicians calculate the epirubicin dose associated with a 5 percent risk of cardiotoxicity for individual patients. Oncologists frequently use anthracyclines, including epirubicin and doxorubicin, to treat breast cancer patients.

More...